WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 530127
Description: Icrocaptide, also known as ITF 1697, is a drug potentially for the treatment of acute myocardial infarction.
MedKoo Cat#: 530127
Chemical Formula: C21H40N8O5
Exact Mass: 484.31
Molecular Weight: 484.6
Elemental Analysis: C, 52.05; H, 8.32; N, 23.12; O, 16.51
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ITF-1697; ITF1697; ITF 1697
IUPAC/Chemical Name: Glycyl-N(sup 2)-ethyl-L-lysyl-L-prolyl-L-arginine
InChi Key: LPKPGXJXCZNDJO-JYJNAYRXSA-N
InChi Code: InChI=1S/C21H40N8O5/c1-2-28(17(30)13-23)16(8-3-4-10-22)19(32)29-12-6-9-15(29)18(31)27-14(20(33)34)7-5-11-26-21(24)25/h14-16H,2-13,22-23H2,1H3,(H,27,31)(H,33,34)(H4,24,25,26)/t14-,15-,16-/m0/s1
SMILES Code: N=C(N)NCCC[C@@H](C(O)=O)NC([C@H]1N(C([C@H](CCCCN)N(C(CN)=O)CC)=O)CCC1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 484.6 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L, Duncker DJ, Simoons ML; PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction).. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. Eur Heart J. 2004 Mar;25(5):392-400. PubMed PMID: 15033251.
2: Syeda B, Kiss K, Modarressy K, Schönau K, Schukro C, Derntl M, Laggner A, Sochor H, Glogar D. Assessment of the safety and efficacy of the novel tetrapeptide ITF-1697 on infarct size after primary PTCA in acute myocardial infarction: a randomised, placebo-controlled pilot trial. Drugs R D. 2004;5(3):141-51. PubMed PMID: 15139775.
3: Yasuda K, Vasko R, Hayek P, Ratliff B, Bicer H, Mares J, Maruyama S, Bertuglia S, Mascagni P, Goligorsky MS. Functional consequences of inhibiting exocytosis of Weibel-Palade bodies in acute renal ischemia. Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F713-21. doi: 10.1152/ajprenal.00541.2011. PubMed PMID: 22160777; PubMed Central PMCID: PMC3311315.
4: Bertuglia S, Ichimura H, Fossati G, Parthasarathi K, Leoni F, Modena D, Cremonesi P, Bhattacharya J, Mascagni P. ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation. Mol Med. 2007 Nov-Dec;13(11-12):615-24. PubMed PMID: 17948065; PubMed Central PMCID: PMC2034195.
5: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.
6: Di Pierro F, d'Atri G, Marcucci F, Leoni F. Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. J Pharmacol Toxicol Methods. 1997 Mar;37(2):91-6. PubMed PMID: 9174984.